Effect of cytomegalovirus reactivation on the time course of systemic host response biomarkers in previously immunocompetent critically ill patients with sepsis: a matched cohort study

Crit Care. 2018 Dec 18;22(1):348. doi: 10.1186/s13054-018-2261-0.

Abstract

Background: Cytomegalovirus (CMV) reactivation in previously immunocompetent critically ill patients is associated with increased mortality, which has been hypothesized to result from virus-induced immunomodulation. Therefore, we studied the effects of CMV reactivation on the temporal course of host response biomarkers in patients with sepsis.

Methods: In this matched cohort study, each sepsis patient developing CMV reactivation between day 3 and 17 (CMV+) was compared with one CMV seropositive patient without reactivation (CMVs+) and one CMV seronegative patient (CMVs-). CMV serostatus and plasma loads were determined by enzyme-linked immunoassays and real-time polymerase chain reaction, respectively. Systemic interleukin-6 (IL-6), IL-8, IL-18, interferon-gamma-induced protein-10 (IP-10), neutrophilic elastase, IL-1 receptor antagonist (RA), and IL-10 were measured at five time points by multiplex immunoassay. The effects of CMV reactivation on sequential concentrations of these biomarkers were assessed in multivariable mixed models.

Results: Among 64 CMV+ patients, 45 could be matched to CMVs+ or CMVs- controls or both. The two baseline characteristics and host response biomarker levels at viremia onset were similar between groups. CMV+ patients had increased IP-10 on day 7 after viremia onset (symmetric percentage difference +44% versus -15% when compared with CMVs+ and +37% versus +4% when compared with CMVs-) and decreased IL-1RA (-41% versus 0% and -49% versus +10%, respectively). However, multivariable analyses did not show an independent association between CMV reactivation and time trends of IL-6, IP-10, IL-10, or IL-1RA.

Conclusion: CMV reactivation was not independently associated with changes in the temporal trends of host response biomarkers in comparison with non-reactivating patients. Therefore, these markers should not be used as surrogate clinical endpoints for interventional studies evaluating anti-CMV therapy.

Keywords: Critically ill; Cytomegalovirus; Host response; Inflammation; Reactivation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / analysis
  • Biomarkers / blood*
  • Chemokine CXCL10 / analysis
  • Chemokine CXCL10 / blood
  • Chi-Square Distribution
  • Cohort Studies
  • Critical Illness
  • Cytomegalovirus / immunology
  • Cytomegalovirus / pathogenicity
  • Cytomegalovirus Infections / blood
  • Cytomegalovirus Infections / diagnosis*
  • Cytomegalovirus Infections / immunology
  • Female
  • Humans
  • Immunity, Humoral / physiology*
  • Intensive Care Units / organization & administration
  • Interleukin 1 Receptor Antagonist Protein / analysis
  • Interleukin 1 Receptor Antagonist Protein / blood
  • Interleukin-10 / analysis
  • Interleukin-10 / blood
  • Interleukin-6 / analysis
  • Interleukin-6 / blood
  • Male
  • Middle Aged
  • Sepsis / immunology*
  • Virus Activation / physiology

Substances

  • Biomarkers
  • CXCL10 protein, human
  • Chemokine CXCL10
  • IL10 protein, human
  • IL6 protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-6
  • Interleukin-10